Topoisomerase II Alpha Inhibition Can Overcome Taxane-Resistant Prostate Cancer through DNA Repair Pathways

Cabazitaxel (CBZ) was approved for the treatment of docetaxel-resistant castration-resistant prostate cancer (CRPC). Researchers explored the optimal treatment for CRPC in the post-cabazitaxel setting using PC3 (CBZ-sensitive) and PC3CR cells (CBZ-resistant).